Placeholder Banner

Some ABCs of PAGs

August 30, 2012
A lot of people, and especially those who have attended BIO events (such as the BIO CEO & Investor Conference, BIO Investor Forum, and the BIO Business Forum) are familiar with the names Michael J. Fox Foundation, FasterCures, ALS Therapy Development Institute, JDRF, and other non-profit Patient Advocacy Groups, or "PAG's".

In case you missed them, two blog posts came up from the Michael J. Fox Foundation and FasterCures that we wanted to share. They explain their goals and programs, and through that, they give a good glimpse into what their roles are in the biotech/research/funding world. The posts are great examples of what their organizations can bring to the table for both companies and people. We hope these articles will provide more information to you on what it is they do, but also why we invite them to attend, present, and partner at our events.

FasterCures blog from August 6th puts it this way: "Free of external pressures, nonprofit foundations are ideally positioned to make relatively high-risk investments that could significantly move a field of research forward and increase the likelihood that other parties also will invest." They also discuss a new software, the Research Acceleration and Innovation Network (TRAIN) Inventory, "a free, Web-based index that catalogues the operational and partnering practices of over 50 leading nonprofits that find and fund cutting-edge medical research."

Read the post:

MJFF's blog from August 13th highlights their new funding program, the Therapeutic Pipeline Program. The blog post is a resource page, so you can find valuable links to the project, such as a recorded conference call on the subject. They also give a couple pretty important numbers: "To date, we have funded over $297 million in research, $77 million of which has been awarded to more than 160 unique, industry-led projects." BIO also just posted a more in-depth look at their initiatives.

Read the posts:

We look forward to seeing what these organizations, and all the great PAGs, can do in biotech!